摘要
目的分析在复发卵巢癌治疗期间选用异环磷酰胺、依托泊苷联合治疗的临床效果。方法100例复发卵巢癌患者,根据随机数字表法分为对照组和观察组,每组50例。对照组患者采用依托泊苷单药治疗,观察组患者在对照组的基础上联合异环磷酰胺治疗。对比两组患者的临床治疗效果、不良反应发生率及血清糖类抗原125(CA125)、血清糖类抗原125Ⅱ(CA125Ⅱ)水平。结果观察组患者临床治疗总有效率为92.00%,高于对照组的76.00%,差异有统计学意义(P<0.05)。观察组患者用药后不良反应发生率为4.00%,低于对照组的16.00%,差异有统计学意义(P<0.05)。观察组CA125(52.96±7.19)U/ml、CA125Ⅱ(54.32±5.74)U/ml低于对照组的(67.64±8.42)、(68.64±6.78)U/ml,差异有统计学意义(P<0.05)。结论复发卵巢癌患者临床治疗期间采用异环磷酰胺+依托泊苷进行治疗具有显著效果,安全性比较高,对减轻患者相关临床症状具有较为理想的效果,在临床中值得广泛推广和应用。
Objective To analyze the clinical effect of ifosfamide combined with etoposide on patients with recurrent ovarian cancer.Methods A total of 100 patients with recurrent ovarian cancer were divided into control group and observation group according to random numerical table,with 50 cases in each group.The control group was treated with etoposide only,and the observation group was also treated with ifosfamide based on the control group.The clinical effect,incidence of adverse reactions,serum carbohydrate antigen 125(CA125)and serum carbohydrate antigen 125Ⅱ(CA125Ⅱ)levels were compared between the two groups.Results The total effective rate of clinical treatment of the observation group was 92.00%,which was higher than 76.00%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions after medication of the observation group was 4.00%,which was lower than 16.00%of the control group,and the difference was statistically significant(P<0.05).CA125(52.96±7.19)U/ml and CA125Ⅱ(54.32±5.74)U/ml of the observation group were lower than(67.64±8.42)and(68.64±6.78)U/ml of the control group,and the difference was statistically significant(P<0.05).Conclusion Ifosfamide combined with etoposide is effective in the treatment of patients with recurrent ovarian cancer and a has relatively ideal effect on alleviating the relevant clinical symptoms of the patient with high safety.It is worthy of widespread promotion and application in clinical practice.
作者
梁红
LIANG Hong(Huludao Central Hospital,Huludao 125000,China)
出处
《中国现代药物应用》
2020年第24期7-9,共3页
Chinese Journal of Modern Drug Application
